Key result
TNFAIP8 preservation protects cardiac function against anthracycline toxicity by reducing oxidative stress and apoptosis.
Why the study?
The cardiomyocyte-intrinsic survival mechanisms that counteract anthracycline-induced cardiotoxicity remain incompletely defined.
Does preservation of TNFAIP8 expression protect cardiomyocytes from doxorubicin-induced cardiotoxicity?
Does preservation of TNFAIP8 expression protect cardiomyocytes from doxorubicin-induced cardiotoxicity?
TNFAIP8 is a critical intrinsic survival factor in cardiomyocytes that protects against anthracycline-induced cardiotoxicity by preserving mitochondrial integrity and limiting apoptosis.
TNFAIP8 preservation may mitigate anthracycline cardiotoxicity; leaves open clinical translation from animal and iPSC models.
Background Anthracycline-induced cardiotoxicity limits the therapeutic efficacy of cancer treatment and is characterized by mitochondrial dysfunction, oxidative stress, inflammatory activation, and cardiomyocyte apoptosis. The cardiomyocyte-intrinsic survival mechanisms that counteract these stress pathways remain incompletely defined. Methods Doxorubicin-induced cardiotoxicity was modeled using human induced pluripotent stem cell–derived cardiomyocytes and a murine model of anthracycline injury. Cardiomyocyte viability, mitochondrial structure and bioenergetics, oxidative stress, inflammatory signaling, and contractile function were assessed using high-content imaging, ultrastructural analysis, metabolic flux measurements, and functional assays. Transcriptomic profiling was performed to identify candidate survival regulators, followed by molecular, genetic, and functional validation in vitro and in vivo. Results Doxorubicin induced dose-dependent cardiomyocyte injury marked by reduced cell survival, increased apoptosis, mitochondrial ultrastructural disruption, impaired oxidative phosphorylation, excessive reactive oxygen species generation, and increased tumor necrosis factor–α secretion. In vivo, doxorubicin exposure resulted in reduced survival and progressive systolic and diastolic dysfunction accompanied by myocardial architectural disorganization and cardiomyocyte loss. Transcriptomic analysis identified TNFAIP8 as a doxorubicin-responsive gene whose expression was reduced in injured cardiomyocytes and myocardium. Loss of TNFAIP8 was sufficient to impair cardiomyocyte viability and phenocopied key features of doxorubicin-induced injury. Conversely, preservation of TNFAIP8 expression was associated with attenuation of oxidative stress–driven inflammatory signaling, reduced FGFR1 activation, and suppression of caspase-3–dependent apoptosis, accompanied by improved cardiomyocyte survival and contractile performance. Conclusions Doxorubicin-induced cardiotoxicity is driven by oxidative stress–associated inflammatory signaling that converges on destabilization of the cardiomyocyte survival factor TNFAIP8, thereby lowering the apoptotic threshold. Maintenance of TNFAIP8 defines a cardiomyocyte-intrinsic survival axis that preserves mitochondrial integrity, limits apoptotic activation, and protects cardiac structure and function under anthracycline stress.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied Anthracycline-induced cardiotoxicity. Doxorubicin / TNFAIP8 manipulation was evaluated on Cardiomyocyte viability, mitochondrial structure, and contractile function. Preservation of TNFAIP8 expression in cardiomyocytes attenuated oxidative stress-driven inflammatory signaling and suppressed apoptosis, protecting cardiac function under anthracycline stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: